Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL... Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. Mehr anzeigen
CONSHOHOCKEN, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced the company will participate in a fireside chat at the H.C. Wainwright 8th...
CONSHOHOCKEN, Pa., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic...
Patients with MASH/NASH treated with Rezdiffra experienced clinically meaningful and statistically significant improvements in emotional well-being and health distressStudy results underscore the...
CONSHOHOCKEN, Pa., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in the Morgan Stanley 22nd Annual Global...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 2.25 | 1.07846426688 | 208.63 | 221.3 | 204.58 | 319631 | 212.58562106 | CS |
| 4 | -24.48 | -10.4010876954 | 235.36 | 248.19 | 204.58 | 271341 | 221.60021408 | CS |
| 12 | -60.215 | -22.2117707815 | 271.095 | 297.25 | 204.58 | 271316 | 244.28924212 | CS |
| 26 | -40.53 | -16.121077125 | 251.41 | 298 | 189 | 364588 | 243.74358783 | CS |
| 52 | 70.8 | 50.5425471159 | 140.08 | 298 | 119.7604 | 426751 | 225.29446395 | CS |
| 156 | 130.09 | 161.022403763 | 80.79 | 322.67 | 52.33 | 352678 | 193.48851422 | CS |
| 260 | 123.64 | 141.723979826 | 87.24 | 322.67 | 52.33 | 273411 | 172.2096069 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
